"MLTX presents a compelling long opportunity driven by a major regulatory catalyst: the FDA has indicated that Moon Lake can establish evidence of sonelokimab's effectiveness for Hidradenitis Suppurativa without requiring additional trials, effectively de-risking the regulatory pathway. This has triggered analyst upgrades including BTIG upgrading to Buy and H. C. Wainwright raising their price target to $32 (from $26) . The stock has surged 32.1% YTD with volume at 2.19x average, showing strong institutional conviction. Technically, RSI at 68.94 with rising momentum and MACD positive at 0.539 confirms bullish momentum. Price is breaking above the upper Bollinger Band ( $17.58) with volume confirmation, a classic breakout signal. The stock is 210% above its 52-week low but still 70% below its 52-week high of $62.75, suggesting significant room to run. M&A speculation adds further upside optionality as the lead asset approaches commercialization."